Madrigal Pharmaceuticals Future Growth
Future criteria checks 5/6
Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 61.4% and 52.5% per annum respectively. EPS is expected to grow by 59.4% per annum. Return on equity is forecast to be -256.8% in 3 years.
Key information
61.4%
Earnings growth rate
59.4%
EPS growth rate
Biotechs earnings growth | 30.8% |
Revenue growth rate | 52.5% |
Future return on equity | -256.8% |
Analyst coverage | Good |
Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 931 | 137 | -96 | -148 | 12 |
12/31/2025 | 351 | -296 | -339 | -460 | 13 |
12/31/2024 | 82 | -459 | -444 | -508 | 14 |
12/31/2023 | N/A | -374 | -326 | -324 | N/A |
9/30/2023 | N/A | -347 | -303 | -303 | N/A |
6/30/2023 | N/A | -330 | -277 | -277 | N/A |
3/31/2023 | N/A | -315 | -259 | -259 | N/A |
12/31/2022 | N/A | -295 | -225 | -225 | N/A |
9/30/2022 | N/A | -274 | -215 | -214 | N/A |
6/30/2022 | N/A | -256 | -201 | -201 | N/A |
3/31/2022 | N/A | -247 | -191 | -190 | N/A |
12/31/2021 | N/A | -242 | -184 | -184 | N/A |
9/30/2021 | N/A | -236 | -191 | -191 | N/A |
6/30/2021 | N/A | -231 | -193 | -193 | N/A |
3/31/2021 | N/A | -219 | -171 | -170 | N/A |
12/31/2020 | N/A | -202 | -158 | -158 | N/A |
9/30/2020 | N/A | -171 | -115 | -115 | N/A |
6/30/2020 | N/A | -134 | -79 | -78 | N/A |
3/31/2020 | N/A | -105 | -66 | -66 | N/A |
12/31/2019 | N/A | -84 | -42 | -42 | N/A |
9/30/2019 | N/A | -68 | -36 | -36 | N/A |
6/30/2019 | N/A | -55 | -30 | -30 | N/A |
3/31/2019 | N/A | -42 | -23 | -23 | N/A |
12/31/2018 | N/A | -33 | -26 | -26 | N/A |
9/30/2018 | N/A | -30 | -25 | -25 | N/A |
6/30/2018 | N/A | -30 | -25 | -25 | N/A |
3/31/2018 | N/A | -32 | -27 | -27 | N/A |
12/31/2017 | N/A | -31 | -22 | -22 | N/A |
9/30/2017 | N/A | -30 | N/A | -22 | N/A |
6/30/2017 | N/A | -36 | N/A | -26 | N/A |
3/31/2017 | N/A | -31 | N/A | -21 | N/A |
12/31/2016 | N/A | -26 | N/A | -18 | N/A |
9/30/2016 | N/A | -21 | N/A | -13 | N/A |
6/30/2016 | N/A | -8 | N/A | -5 | N/A |
3/31/2016 | N/A | -7 | N/A | -3 | N/A |
12/31/2015 | N/A | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YDO1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: YDO1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: YDO1 is expected to become profitable in the next 3 years.
Revenue vs Market: YDO1's revenue (52.5% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: YDO1's revenue (52.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: YDO1 is forecast to be unprofitable in 3 years.